CLINICAL EFFICACY OF PAROXETINE COMBINED WITH PRAMIPEXOLE AND MADOPAR IN TREATING PARKINSON’S PATIENTS COMPLICATED WITH DEPRESSIVE DISORDER AND ITS INFLUENCE ON THEIR PROGNOSTIC QUALITY OF LIFE

Hongxing Wang¹, Yanmin Zhao¹, Wei Guo², Chuanqing Yu^{*, 1}, Huanhuan Jia¹ 

¹Department of geriatric rehabilitation, Liaocheng Fourth People's Hospital, Liaocheng 252000, P.R.China - ²Family ward Deparement, Liaocheng Fourth People’s Hospital, Liaocheng 252000, P.R.China

Objective: This study was designed to explore the clinical efficacy of paroxetine combined with pramipexole and madopar in the treatment of Parkinson’s patients complicated with depressive disorder and its influence on their prognostic quality of life. 

Methods: A total of 103 Parkinson’s patients complicated with depressive disorder who came to our hospital from March 2015 to July 2018 were selected. Among them, 57 patients treated with paroxetine combined with pramipexole were group A, and 56 patients treated with paroxetine combined with madopar were group B. After 12 weeks of treatment, the efficacy, living ability, dyskinesia, depressive state, treatment compliance, adverse reactions and quality of life of patients in the two groups were recorded, evaluated and compared. 

Results: The total effective rate of group A was significantly higher than that of group B (P<0.05). After treatment, the UPDRS II score, UPDRS III score, HAMD score and MADRS score of group A were significantly lower than those before treatment, but the UPDRS II score, UPDRS III score, HAMD score and MADRS score of group A were significantly lower than those of group B (P<0.05). The treatment compliance rate of group A was significantly higher than that of group B (P<0.05), there was no significant difference in the incidence rate of adverse reactions between the two groups (P>0.05), and the life quality score of patients in group A was significantly higher than those in group B (P<0.05). 

Conclusion: Paroxetine combined with pramipexole has better efficacy on Parkinson’s disease complicated with depressive disorder than that combined with madopar, hence, it can effectively improve the depressive state and Parkinson’s symptoms of patients and also has good safety, which is worthy of clinical promotion.